May 16, 2023 / 05:00PM GMT
Reni Benjamin - JMP Securities LLC - Analyst
We'll go ahead and get started. Good afternoon, everyone. Welcome to the second day of the JMP Securities Life Sciences Conference.
Our next presenting company is Verastem Oncology. Verastem is developing several molecules. One, which targeting the RAS pathway. The other one, the FAK inhibitor, which I remember from way back when. Here to tell us about the company is Dan Paterson, President and Chief Operating Officer.
Dan Peterson - Verastem, Inc. - President & COO
Thanks, Ren. It's a good to actually get out between the pandemic and execution. Haven't been out in quite a while and commute in New York for the first time in three years. I noticed ties are missing and there's no cabs anywhere. So it's a little different.
Anyway, very exciting time for Verastem. I'm glad to tell you an update on the story. Safe Harbor. I will be talking about forward-looking statements.
So it is a really exciting time for us. We're really well positioned for what we're hoping will be an uptick in the
Verastem Inc at JMP Securities Life Sciences Conference Transcript
May 16, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers